S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
NASDAQ:QDEL

QuidelOrtho (QDEL) Stock Price, News & Analysis

$48.18
-0.08 (-0.17%)
(As of 03:21 PM ET)
Today's Range
$48.14
$49.08
50-Day Range
$41.76
$72.25
52-Week Range
$41.75
$98.67
Volume
284,686 shs
Average Volume
1.02 million shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.60

QuidelOrtho MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
26.9% Upside
$61.60 Price Target
Short Interest
Healthy
3.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.90mentions of QuidelOrtho in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$99,652 Bought Last Quarter
Proj. Earnings Growth
61.87%
From $2.57 to $4.16 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

20th out of 939 stocks

Diagnostic Substances Industry

1st out of 13 stocks

QDEL stock logo

About QuidelOrtho Stock (NASDAQ:QDEL)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

QDEL Stock Price History

QDEL Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
QDEL Apr 2024 50.000 call
QDEL Apr 2024 70.000 call
QDEL Apr 2024 65.000 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
QuidelOrtho to lay off employees after firing CEO
QuidelOrtho: Uncertainty Reigns
Analyst Scoreboard: 6 Ratings For QuidelOrtho
See More Headlines
Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:QDEL
CUSIP
74838J10
Employees
7,100
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$61.60
High Stock Price Target
$81.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+27.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-10,100,000.00
Pretax Margin
-0.97%

Debt

Sales & Book Value

Annual Sales
$3.00 billion
Cash Flow
$11.28 per share
Book Value
$74.92 per share

Miscellaneous

Free Float
65,044,000
Market Cap
$3.22 billion
Optionable
Optionable
Beta
0.11

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Robert J. Bujarski J.D. (Age 55)
    Interim President, Executive VP & COO
    Comp: $2.62M
  • Mr. Joseph M. Busky CPA (Age 56)
    Chief Financial Officer
    Comp: $1.47M
  • Ms. Michelle A. Hodges (Age 63)
    Senior VP, General Counsel & Secretary
    Comp: $1.8M
  • Dr. Werner Kroll Ph.D. (Age 67)
    Senior Vice President of Research & Development
    Comp: $1.25M
  • Mr. Michael S. Iskra (Age 54)
    Interim CEO, Executive VP & Chief Commercial Officer
  • Ms. Louise M. Brandy
    Chief Information Officer
  • Mr. Patrick E. Klein
    Chief Administrative Officer
  • Ruben Argueta
    Director of Investor Relations
  • Mr. William J. FerenczyMr. William J. Ferenczy (Age 68)
    Point of Care Business Unit Leader
  • Ms. Tamara A. Ranalli (Age 51)
    Molecular Diagnostics Business Unit Leader

QDEL Stock Analysis - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings
or view top-rated stocks.

What is QuidelOrtho's stock price target for 2024?

7 brokers have issued 12-month price targets for QuidelOrtho's shares. Their QDEL share price targets range from $37.00 to $81.00. On average, they anticipate the company's share price to reach $61.60 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price.
View analysts price targets for QDEL
or view top-rated stocks among Wall Street analysts.

How have QDEL shares performed in 2024?

QuidelOrtho's stock was trading at $73.70 at the start of the year. Since then, QDEL stock has decreased by 34.1% and is now trading at $48.54.
View the best growth stocks for 2024 here
.

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our QDEL earnings forecast
.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) posted its quarterly earnings results on Tuesday, February, 13th. The company reported $1.17 EPS for the quarter, missing the consensus estimate of $2.01 by $0.84. The business had revenue of $742.60 million for the quarter, compared to analyst estimates of $796.91 million. QuidelOrtho had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 5.54%. The firm's revenue was down 14.3% compared to the same quarter last year. During the same period last year, the firm posted $1.74 earnings per share.

What guidance has QuidelOrtho issued on next quarter's earnings?

QuidelOrtho issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 2.400-3.070 for the period, compared to the consensus EPS estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

Who are QuidelOrtho's major shareholders?

QuidelOrtho's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.25%), Vanguard Group Inc. (7.24%), Senvest Management LLC (4.49%), Burgundy Asset Management Ltd. (1.74%), Rubric Capital Management LP (1.47%) and LGT Capital Partners LTD. (1.43%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy.
View institutional ownership trends
.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QDEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners